TR201908736T4 - Trk-inhibe eden bileşiğin asit eklenmiş tuzu. - Google Patents

Trk-inhibe eden bileşiğin asit eklenmiş tuzu. Download PDF

Info

Publication number
TR201908736T4
TR201908736T4 TR2019/08736T TR201908736T TR201908736T4 TR 201908736 T4 TR201908736 T4 TR 201908736T4 TR 2019/08736 T TR2019/08736 T TR 2019/08736T TR 201908736 T TR201908736 T TR 201908736T TR 201908736 T4 TR201908736 T4 TR 201908736T4
Authority
TR
Turkey
Prior art keywords
trk
compound
acid
inhibiting compound
added salt
Prior art date
Application number
TR2019/08736T
Other languages
English (en)
Inventor
Takeuchi Jun
Itadani Satoshi
Ikura Masahiro
Higashino Masato
Kijima Hideomi
Ono Shizuka
Yasuhiro Tetsuya
Nagaura Takeshi
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of TR201908736T4 publication Critical patent/TR201908736T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

Trk-ilişkili hastalıklar için bir profilaktik ve/veya terapötik ajan sağlamak için, mevcut buluş selektif bir Trk-inhibe edici aktiviteye sahip olan ve ısrarlı bir şekilde NGF vasküler hiper permeabiliteyi inhibe eden ve bir ilaç etkileşimine sahip olmayan ve buna ilaveten de serbest bazlara karşın çözünürlük ve absorbe edilebilirlikte mükemmel olan bir bileşik sağlamaktadır. Mevcut buluşun bileşiği selektif bir Trk-inhibe edici aktiviteye sahip olan ve ısrarlı bir şekilde NGF vasküler hiper permeabiliteyi inhibe eden ve bir ilaç etkileşimine sahip olmayan ve buna ilaveten de serbest bazlara karşın çözünürlük ve absorbe edilebilirlikte mükemmel olan bir bileşiktir ve bundan dolayı da Trk-ilişkili hastalıklar için bir profilaktik ve/veya terapötik ajandır.
TR2019/08736T 2014-08-18 2015-08-17 Trk-inhibe eden bileşiğin asit eklenmiş tuzu. TR201908736T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014165622 2014-08-18

Publications (1)

Publication Number Publication Date
TR201908736T4 true TR201908736T4 (tr) 2019-07-22

Family

ID=55350699

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08736T TR201908736T4 (tr) 2014-08-18 2015-08-17 Trk-inhibe eden bileşiğin asit eklenmiş tuzu.

Country Status (22)

Country Link
US (1) US10399959B2 (tr)
EP (1) EP3184519B1 (tr)
JP (2) JP5979335B2 (tr)
KR (1) KR20170042591A (tr)
CN (2) CN106573913B (tr)
AU (1) AU2015304438B2 (tr)
BR (2) BR122017020365A2 (tr)
CA (1) CA2958423A1 (tr)
DK (1) DK3184519T3 (tr)
ES (1) ES2732026T3 (tr)
HU (1) HUE045237T2 (tr)
IL (2) IL250603A0 (tr)
MX (1) MX2017002199A (tr)
PH (2) PH12017500287A1 (tr)
PL (1) PL3184519T3 (tr)
PT (1) PT3184519T (tr)
RU (1) RU2708236C2 (tr)
SG (1) SG11201701208WA (tr)
TR (1) TR201908736T4 (tr)
TW (2) TWI573794B (tr)
WO (1) WO2016027754A1 (tr)
ZA (1) ZA201701174B (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
RS62869B1 (sr) 2008-10-22 2022-02-28 Array Biopharma Inc Substituisana jedinjenja pirazolo[1,5-a]pirimidina kao inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
TWI567068B (zh) 2013-02-19 2017-01-21 小野藥品工業股份有限公司 Ｔｒｋ抑制化合物
HRP20230271T1 (hr) 2014-11-16 2023-06-09 Array Biopharma, Inc. Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogen sulfata
US20180140604A1 (en) 2015-06-01 2018-05-24 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
JPWO2017155018A1 (ja) * 2016-03-11 2019-01-17 小野薬品工業株式会社 Ｔｒｋ阻害剤抵抗性の癌治療剤
KR102400423B1 (ko) 2016-04-04 2022-05-19 록쏘 온콜로지, 인코포레이티드 (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형
SG11201808676RA (en) 2016-04-04 2018-11-29 Loxo Oncology Inc Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
PE20190437A1 (es) 2016-05-18 2019-03-27 Loxo Oncology Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) * 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
WO2019049891A1 (ja) 2017-09-06 2019-03-14 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN113194928A (zh) 2018-07-31 2021-07-30 罗索肿瘤学公司 (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN113884584B (zh) * 2020-08-07 2023-07-28 北京泰德制药股份有限公司 一种氟比洛芬和/或氟比洛芬酯含量的检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP6160613B2 (ja) 2012-04-26 2017-07-12 小野薬品工業株式会社 Ｔｒｋ阻害化合物
TWI567068B (zh) 2013-02-19 2017-01-21 小野藥品工業股份有限公司 Ｔｒｋ抑制化合物

Also Published As

Publication number Publication date
TW201623284A (zh) 2016-07-01
BR112017003302A2 (pt) 2017-11-28
CN110655502A (zh) 2020-01-07
AU2015304438B2 (en) 2019-06-20
WO2016027754A1 (ja) 2016-02-25
RU2017104918A3 (tr) 2019-03-06
PT3184519T (pt) 2019-07-01
BR122017020365A2 (pt) 2019-09-10
PH12017500287A1 (en) 2017-06-28
EP3184519A4 (en) 2018-03-07
ZA201701174B (en) 2019-06-26
JP5979329B1 (ja) 2016-08-24
CA2958423A1 (en) 2016-02-25
EP3184519B1 (en) 2019-04-24
TWI573794B (zh) 2017-03-11
JPWO2016027754A1 (ja) 2017-04-27
PL3184519T3 (pl) 2019-09-30
HUE045237T2 (hu) 2019-12-30
CN106573913B (zh) 2019-11-19
ES2732026T3 (es) 2019-11-20
EP3184519A1 (en) 2017-06-28
JP2016155828A (ja) 2016-09-01
RU2708236C2 (ru) 2019-12-05
KR20170042591A (ko) 2017-04-19
RU2017104918A (ru) 2018-09-23
SG11201701208WA (en) 2017-03-30
MX2017002199A (es) 2017-08-18
IL250603A0 (en) 2017-04-30
US20170240527A1 (en) 2017-08-24
DK3184519T3 (da) 2019-07-08
JP5979335B2 (ja) 2016-08-24
US10399959B2 (en) 2019-09-03
TW201613897A (en) 2016-04-16
AU2015304438A1 (en) 2017-03-09
CN106573913A (zh) 2017-04-19
PH12017501720A1 (en) 2019-09-30
TWI560185B (en) 2016-12-01
IL254351A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
TR201908736T4 (tr) Trk-inhibe eden bileşiğin asit eklenmiş tuzu.
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500723B1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2015014033A (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016501702A1 (en) Pyrazole amide derivative
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12018501709A1 (en) Naphthridinedione derivatives
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
BR112017005518A2 (pt) ?derivados de 7-(morfolinil)-2-(n-piperazinil) metil-tieno [2, 3-c] piridina como drogas anticancerígenas?
PH12016501645A1 (en) Aminopyrazolone derivative
TR201906180T4 (tr) Glikozaminoglikanların karboksilatlı türevleri ve bunların ilaç olarak kullanımı.
EA201690950A1 (ru) Средства и способ предотвращения миграции танина из древесины
BR112015021432A2 (pt) compostos antivirais
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена